Oncolys BioPharma Inc.
4588.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | 0.21 | -0.06 | 0.36 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -50.53 | -29.61 | -17.27 | -24.94 |
| Quality | ||||
| ROIC | -14.39% | -26.45% | -35.13% | -14.66% |
| Gross Margin | 0.00% | 99.85% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -51.79% | -64.02% | -66.27% | -68.20% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.36 | 2.02 | 1.76 | 4.23 |
| Interest Coverage | -200.75 | -400.27 | -723.69 | -394.81 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.01 | 0.00 | 0.10 |
| Cash Conversion Cycle | 4,091.79 | 10,821.05 | -374,724.00 | -9,870.83 |